Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000; 96(8):2691-2696.

Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338(23):1663-1671.

Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous
mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2003; 101(10):3809-3817.

Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A et al. Value of high-dose cytarabine during interval therapy of a
Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European
Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol 2001; 19(7):1935-1942.

Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment
of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group
phase 3 trial. Blood 2002; 99(8):2734-2739.

Howard SC, Gajjar AJ, Cheng C, Kritchevsky SB, Somes GW, Harrison PL et al. Risk factors for traumatic and bloody lumbar puncture in children with
acute lymphoblastic leukemia. JAMA 2002; 288(16):2001-2007.

Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000; 12(1):3-12.

Reiter A, Schrappe M, Ludwig WD, Hiddemann W, Sauter S, Henze G et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84(9):3122-3133.

Gale KB, Ford AM, Repp R, Borkhardt A, Keller C, Eden OB et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A 1997; 94(25):13950-13954.

Ross JA. Dietary flavonoids and the MLL gene: A pathway to infant leukemia? Proc Natl Acad Sci U S A 2000; 97(9):4411-4413.

Gajjar A, Harrison PL, Sandlund JT, Rivera GK, Ribeiro RC, Rubnitz JE et al. Traumatic lumbar puncture at diagnosis adversely affects outcome in
childhood acute lymphoblastic leukemia. Blood 2000; 96(10):3381-3384.

Pui CH, Campana D, Crist WM. Toward a clinically useful classification of the acute leukemias. Leukemia 1995; 9(12):2154-2157.

Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80(9):1717-1726.

 Toyoda Y, Manabe A, Tsuchida M, Hanada R, Ikuta K, Okimoto Y et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000; 18(7):1508-1516.

Relling MV, Rubnitz JE, Rivera GK, Boyett JM, Hancock ML, Felix CA et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354(9172):34-39.

Wheeler K, Richards S, Bailey C, Chessells J. Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experience. Medical Research Council Working Party on Childhood Leukaemia. Br J Haematol 1998; 101(1):94-103.

Arico M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002; 100(2):420-426.

Silverman LB, Gelber RD, Dalton VK, Asselin BL, Barr RD, Clavell LA et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97(5):1211-1218.